Review paper

Recent Advances in Lipid-Based Nanosystems for Gemcitabine and Gemcitabine–Combination Therapy

Volume: 11, Issue: 3, Pages: 597 - 597
Published: Feb 27, 2021
Abstract
The anti-metabolite drug gemcitabine is widely used for the treatment of a variety of cancers. At present, gemcitabine is administered as a hydrochloride salt that is delivered by slow intravenous injection in cycles of three or four weeks. Although regarded as a ‘front-line’ chemotherapeutic agent, its efficacy is hampered by poor target cell specificity, sub-optimal cellular uptake, rapid clearance from circulation, the development of...
Paper Details
Title
Recent Advances in Lipid-Based Nanosystems for Gemcitabine and Gemcitabine–Combination Therapy
Published Date
Feb 27, 2021
Volume
11
Issue
3
Pages
597 - 597
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.